Pipeline Remepy’s hybrid Parkinson’s therapy poised for phase 3 PharmaphorumRemepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.NeuroscienceRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) Pharmaphorum Remepy’s Hybridopa therapy for Parkinson’s, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing updateNext: ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis Related Stories Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
